186 related articles for article (PubMed ID: 36039449)
1. Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Tatsuki S; Shoji T; Abe M; Tomabechi H; Takatori E; Kaido Y; Nagasawa T; Kagabu M; Aida T; Baba T
Anticancer Res; 2022 Sep; 42(9):4603-4610. PubMed ID: 36039449
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of sequential chemotherapy efficacy in ovarian epithelial carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma].
Shen XY; Li XP; Wang Y; Wu Y; Li Y; Yang YC; Wei LH; Fan Y; Tang ZQ
Zhonghua Fu Chan Ke Za Zhi; 2024 May; 59(5):383-390. PubMed ID: 38797568
[No Abstract] [Full Text] [Related]
3. Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer.
Kobayashi-Kato M; Yunokawa M; Bun S; Miyasaka N; Kato T; Tamura K
Cancer Chemother Pharmacol; 2019 Jul; 84(1):33-39. PubMed ID: 30982097
[TBL] [Abstract][Full Text] [Related]
4. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
5. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract][Full Text] [Related]
6. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T; Takatori E; Nagasawa T; Kagabu M; Baba T; Shigeto T; Matsumura Y; Shimizu D; Terada Y; Seino M; Ohta T; Nagase S; Shigeta S; Tokunaga H; Shimada M; Kaiho-Sakuma M; Furukawa S; Soeda S; Watanabe T; Takahashi F; Yokoyama Y
Int J Clin Oncol; 2022 Dec; 27(12):1874-1880. PubMed ID: 36214925
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
[TBL] [Abstract][Full Text] [Related]
8. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Griffiths RW; Zee YK; Evans S; Mitchell CL; Kumaran GC; Welch RS; Jayson GC; Clamp AR; Hasan J
Int J Gynecol Cancer; 2011 Jan; 21(1):58-65. PubMed ID: 21178570
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
Wenham RM; Lapolla J; Lin HY; Apte SM; Lancaster JM; Judson PL; Gonzalez-Bosquet J; Herschberger A; Havrilesky LJ; Secord AA
Gynecol Oncol; 2013 Jul; 130(1):19-24. PubMed ID: 23623830
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
Cowan M; Swetzig WM; Adorno-Cruz V; Pineda MJ; Neubauer NL; Berry E; Lurain JR; Shahabi S; Taiym D; Nelson V; O'Shea KL; Kocherginsky M; Matei D
Gynecol Oncol; 2021 Oct; 163(1):57-63. PubMed ID: 34419285
[TBL] [Abstract][Full Text] [Related]
12. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
13. A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.
Nanki Y; Nomura H; Iwasa N; Saotome K; Dozen A; Yoshihama T; Hirano T; Hashimoto S; Chiyoda T; Yamagami W; Kataoka F; Aoki D
Jpn J Clin Oncol; 2021 Jan; 51(1):54-59. PubMed ID: 32776094
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
Taylor SE; Chu T; Elvin JA; Edwards RP; Zorn KK
Gynecol Oncol; 2020 Jan; 156(1):32-37. PubMed ID: 31739991
[TBL] [Abstract][Full Text] [Related]
15. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Perez RP; Bauer TM; Ruiz-Soto R; Birrer MJ
J Clin Oncol; 2017 Apr; 35(10):1112-1118. PubMed ID: 28029313
[TBL] [Abstract][Full Text] [Related]
16. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C; Charakorn C; Chittithaworn S; Lertkhachonsuk AA
J Obstet Gynaecol; 2022 Aug; 42(6):2331-2335. PubMed ID: 35470751
[TBL] [Abstract][Full Text] [Related]
18. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
McNeish IA; Ledermann JA; Webber L; James L; Kaye SB; Hall M; Hall G; Clamp A; Earl H; Banerjee S; Kristeleit R; Raja F; Feeney A; Lawrence C; Dawson-Athey L; Persic M; Khan I
Ann Oncol; 2014 Oct; 25(10):1988-1995. PubMed ID: 25070546
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Enomoto T; Abe M; Okamoto A; Nagasawa T; Oishi T; Nagase S; Mori M; Inokuchi Y; Kamiura S; Komiyama S; Takeshima N; Sugiyama T
Cancer Sci; 2022 Jan; 113(1):240-250. PubMed ID: 34716979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]